Warning letter · FDA Warning Letters, Historical Archive

SuperHealthGuard and Loyal Great International Ltd.: FDA Warning Letter 608633 (Jun 26, 2020)

Agency action: Jun 26, 2020Record ID: fda_warning_-1eeb1fdaeaf67289
View official source ↗

What happened

Original notice title

SuperHealthGuard and Loyal Great International Ltd. MARCS-CMS 608633, June 26, 2020

From the archived source record

Based on our review, this product is an unapproved new drug sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, this product is a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. § 352. We request that you take immediate action to cease the sale of such unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Some examples of the claims on your website that establish the intended use of your product and misleadingly represent it as safe and/or effective for the treatment or prevention of COVID-19 include: • “According to several clinical experiment [ sic ], Lianhua Qingwen Capsule is effective and can help COVID-19 patients recover. Third, the Lianhua Qingwen jiaonang capsule can shorten fever & coughing time.” [from your website [see original source] You should take immediate action to correct the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation.

What the official notice says to do

Check the original notice for the instructions that apply to the named product, company, and affected lots.

Read the official notice →

Status and source details

Status recorded in the archive
Historical warning letter; closeout not established by annual index
Source checked
Jul 16, 2026
Record revision
acbf3178f9bb

This is a dated record. Its current status may have changed since the source was captured. A record applies to its stated scope; it is not a safety rating for every product from a company.

Sources, dates, and coverage →

What is affected

Product
a traditional Chinese medicine (TCM) product; Lianhua Qingwen Capsule
Company
SuperHealthGuard and Loyal Great International Ltd.
Lot / identifier
The source does not specify this field.
Market / distribution
The source does not specify this field.